Case Collection Study for Collecting Images for the Development and Validation of Computer Aided Detection Software

NCT ID: NCT00756834

Last Updated: 2020-08-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

135 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-11-30

Study Completion Date

2020-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objective is to assess the performance of the MammoDetector Pro to correctly mark biopsy-proven breast cancers imaged on the Siemens Mammomat Novation FFDM system compared to conventional film-screen mammography.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study design is a controlled study. The study is designed to demonstrate that the performance of the MammoDetector™ Pro on biopsy-proven malignant cases obtained with the Siemens Mammomat NovationDR FFDM system is not inferior to its performance on biopsy-proven malignant cases obtained with conventional film-screen mammography (FSM). The overall sensitivity of the MammoDetector™ Pro with both imaging modalities will be compared. Furthermore, the study is designed to demonstrate that the false marks noted by the MammoDetector™ Pro on routine screening "Normal" cases obtained with the FFDM system is not inferior those marked by the software on routine screening "Normal" cases obtained with conventional film-screen mammography (FSM).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mammography Image Collection

Acquired images

Screening

Intervention Type DEVICE

The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review

CAD Radiologist Reader

Retrospective reader study

Screening

Intervention Type DEVICE

The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Screening

The MammoDetector™ Pro is a computer-aided software intended to identify and mark regions of interest on standard mammographic views to bring them to the attention of the radiologist after the initial reading has been completed. Thus, the device assists the radiologist in minimizing observational oversights by identifying areas on the original mammogram that may warrant a second review

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Mammograms obtained from women 40 years of age and over;
2. Mammograms obtained from women only;
3. There are at least four standard views (right cranio-caudal \[RCC\], right medio-lateral oblique \[RMLO\], left cranio-caudal \[LCC\], left medio-lateral oblique \[LMLO\]) of the breast;
4. Informed consent is obtained.

Mammograms of biopsy-proven cancer cases will be considered eligible for inclusion in the study if they meet the following criteria:
5. Biopsy-proven malignant case that was assigned a BI-RADS category 4 or 5 with a suspicious lesion and the corresponding pathology report for the suspicious lesion is available.
6. Cases which have one or more lesion.

Routine screening "Normal" cases will be considered eligible for inclusion in the study if they meet the following criteria:
7. The case is a routine screening mammogram assigned a BI-RADS category 1 or 2 by a certified radiologist

Exclusion Criteria

Cases are excluded from the study if they have any of the following conditions:

1. Mammographic needle projection or pre-biopsy markings are evident on the mammogram (these may cause false marks).
2. The mammograms include artifacts created by breast implant.
3. The mammograms are of poor quality (e.g., the digital image has very poor contrast);

Mammograms of biopsy-proven cancer cases will be excluded from the study if they have any of the following conditions:
4. Cases in which the lesion is only palpable or visible by another modality (e.g., Ultrasound, MRI).
5. The pathology is not related to a specific region. That is, there is more than one biopsy region and the pathology reports cannot be related to the appropriate mammographic lesion. For example, a mammogram with multiple lesions and multiple related pathology reports on the same date and it is not clear which pathology report belongs to each lesion.
6. The pathology report is more than three months after the FFDM or FSM mammogram.
7. The mammogram was performed for the purpose of planning cancer therapy (e.g., radiation) (BIRADS 6).
8. Cases in which the lesion is characterized as an architectural distortion. -
Minimum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Siemens Medical Solutions

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Louise Ebbert

Role: STUDY_DIRECTOR

Siemens Medical Solutions

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Siemens Medical Solutions

Malvern, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SMS-SP04-04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.